Epidemiology of acute myeloid leukemia: Recent progress and enduring challenges.

@article{Shallis2019EpidemiologyOA,
  title={Epidemiology of acute myeloid leukemia: Recent progress and enduring challenges.},
  author={Rory Michael Shallis and Rong Wang and Amy J. Davidoff and Xiaomei Ma and Amer M. Zeidan},
  journal={Blood reviews},
  year={2019},
  volume={36},
  pages={
          70-87
        }
}
Exciting times ahead for older patients with acute myeloid leukemia: azacitidine and venetoclax followed by allogeneic hematopoietic cell transplantation
TLDR
Venetoclax-based combinations are rendered the new standard of care in older adults with newly diagnosed AML, despite the increased risk of myelosuppression and febrile neutropenia, and relapses still occur with more resistant clones.
Deciphering the Therapeutic Resistance in Acute Myeloid Leukemia
TLDR
The latest insights in AML biology concerning refractoriness to therapies with a specific focus on cytarabine and daunorubicin which still represent milestones agents for inducing therapeutic response and disease eradication are reviewed.
Therapy-Related Acute Myeloid Leukemia Diagnosed at Postmortem in a Long-term Survivor of Advanced Hepatocellular Carcinoma
TLDR
The microscopic examination of the autopsy samples revealed extensive extramedullary infiltration of leukemia, which was confirmed as an AML by a series of ancillary immunohistochemical staining, which illustrates the importance of careful hematologic observation in cancer survivors.
Is outcome of older people with acute myeloid leukemia improving with new therapeutic approaches and stem cell transplantation?
TLDR
Appropriate selection among different options on the basis of clinical fitness and molecular findings at diagnosis as well as at relapse would result in improvement of therapeutic results, sparing unnecessary toxicity and optimizing health systems resources.
Maintenance therapies in acute myeloid leukemia: the renaissance of an old therapeutic concept
TLDR
Maintenance therapies following intensive chemotherapy or allo-HCT offer a new therapeutic paradigm for an increasing number of AML patients and have been shown to result in an OS benefit in selected patients.
The Current Understanding of and Treatment Paradigm for Newly-Diagnosed TP53-Mutated Acute Myeloid Leukemia
TLDR
This review discusses the considerations behind the study of concurrent cytogenetic risk and predicted TP53 allelic state, measurable residual disease status and the impact of conditioning intensity for patients proceeding to allogeneic hematopoietic stem cell transplantation, and offers the current treatment approach to TP53-mutated AML.
The clinical profile, management, and outcome of febrile neutropenia in acute myeloid leukemia from resource constraint settings
TLDR
The number of days required to develop febrile neutropenia was inversely associated with overall survival (OS); however, when compared, there was no statistically significant difference in OS between patients developing fever on day-10 and day-25, emphasizing the importance of preventive measures against infections.
Molecular Monitoring in Acute Myeloid Leukemia Patients Undergoing Matched Unrelated Donor: Hematopoietic Stem Cell Transplantation
TLDR
Analysis of data of AML patients who underwent matched unrelated donor (MUD) HSCT since the introduction of this procedure in the Republic of North Macedonia suggests regular MRD monitoring helps predict impending relapse and direct future treatment strategies.
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 188 REFERENCES
‘Acute myeloid leukemia: a comprehensive review and 2016 update'
TLDR
The identification of recurrent genetic mutations, such as FLT3-ITD, NMP1 and CEBPA, has helped refine individual prognosis and guide management and here, the major recent advances in the treatment of AML are reviewed.
Treated secondary acute myeloid leukemia: a distinct high-risk subset of AML with adverse prognosis.
TLDR
Future AML trial designs should accommodate ts-AML as a distinct subgroup, as it represents a very high-risk category, even in younger AML patients.
Acute leukemia in adult Hispanic Americans: a large-population study
TLDR
The varied distribution of AL among these ethnic groups suggests that host susceptibility factors are critical determinants of disease in one group, but not in another, and the extent to which the environment interacts with these factors is unknown.
Acute myeloid leukemia: Epidemiology and etiology
TLDR
To estimate outcome and discuss informed treatment decisions with AML patients of different age groups and different biologic risk categories, it is mandatory to consider that the outcome results reported in clinical trials were until now heavily biased toward younger patients, whereas the overall dismal prognosis documented in population‐based studies most likely reflects the exclusion of older patients from aggressive treatment.
Epidemiology and Clinical Significance of Secondary and Therapy-Related Acute Myeloid Leukemia: A National Population-Based Cohort Study.
TLDR
The results support that de novo AML, sAML, and tAML are biologically and prognostically distinct subtypes of AML and should be integrated in treatment recommendations for these patients.
Age and acute myeloid leukemia.
TLDR
The combination of a poor performance status and advanced age identified a group of patients with a very high likelihood of dying within 30 days of initiating induction therapy, arguing for age-specific assessments when evaluating therapies for AML.
The incidence of secondary leukemias.
TLDR
Assessment of the risk of secondary leukemia should become part of any therapeutic plan for cancer patients, and alkylating agents, nitrosureas and procarbazine appear to have the highest leukemogenic potential.
Therapy-related myelodysplasia and acute myeloid leukemia. Cytogenetic characteristics of 115 consecutive cases and risk in seven cohorts of patients treated intensively for malignant diseases in the Copenhagen series.
TLDR
There may be a synergistic leukemogenic effect between the two types of drug, and in patients with germ cell tumors treated with etoposide, cisPlatin and bleomycin, reassessment suggested the risk of leukemia to increase exponentially with increasing doses of cisplatin and etopOSide.
...
1
2
3
4
5
...